期刊
LEUKEMIA & LYMPHOMA
卷 59, 期 4, 页码 813-820出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2017.1349907
关键词
Acute myeloid leukemia; relapsed; refractory; purine nucleoside analogues; clofarabine; fludarabine
资金
- MD Anderson Cancer Center Support Grant [CA016672]
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
The purine nucleoside analogues clofarabine and fludarabine are active in acute myeloid leukemia (AML). We conducted a phase I/II randomized study of idarubicin and cytarabine with either clofarabine (CIA) or fludarabine (FIA) for relapsed or refractory AML. Clofarabine 15mg/m(2) was identified as the recommended phase II dose. Eighty-one patients were assigned using adaptive randomization to CIA (n=48) or FIA (n=33). The complete response (CR)/CR without platelet recovery rate did not differ between CIA and FIA (38% versus 30%, respectively; p=.50). In both arms, more than half of patients who had received only one prior line of therapy achieved remission. The median event-free survival for CIA and FIA was 2.0 and 1.9 months (p=.48), and the median overall survival was 6.3 and 4.7 months, respectively (p=.28). No significant differences in adverse events or early mortality rates were observed. Overall, CIA and FIA resulted in similar response rates and survival in patients with relapsed/refractory AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据